Next Article in Journal
Pilot Production of Mesenchymal Stem/Stromal Freeze-Dried Secretome for Cell-Free Regenerative Nanomedicine: A Validated GMP-Compliant Process
Previous Article in Journal
Neuronal Ceroid Lipofuscinoses: Connecting Calcium Signalling through Calmodulin
Previous Article in Special Issue
Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets
Article Menu

Export Article

Open AccessFeature PaperReview
Cells 2018, 7(11), 189;

Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies

Experimental Haematology, Leeds Institute of Medical Research at St. James’s, School of Medicine, University of Leeds, Leeds LS9 7TF, UK
Author to whom correspondence should be addressed.
Received: 12 October 2018 / Revised: 26 October 2018 / Accepted: 26 October 2018 / Published: 30 October 2018
(This article belongs to the Special Issue NF-κB in Cancer)
Full-Text   |   PDF [1276 KB, uploaded 31 October 2018]   |  


Lymphoid malignancies frequently harbor genetic mutations leading to aberrant activation of nuclear factor-κB (NF-κB) signaling; in normal cells, this pathway has important roles in the control of cell growth, survival, stress responses, and inflammation. Malignancies with mutations in NF-κB pathway components can derive from all cell stages of mature B-cell development; however, aberrant NF-κB activity is particularly prevalent in aggressive subtypes of non-Hodgkin lymphoma and myeloma. NF-κB activation is mediated by two separate pathways, the canonical and alternative pathway, and five downstream transcription factor subunits. Recent findings implicate a predominant role for distinct NF-κB pathways and subunits in certain lymphoma subtypes and myeloma; findings which are complemented by the realization that individual NF-κB subunits can have unique, non-redundant biological roles in the putative tumor precursor cells, including activated B cells, germinal center B cells and plasma cells. The knowledge gained from these studies may be exploited for the development of therapeutic strategies to inhibit aberrant NF-κB activity at the level of the transcription-factor subunits and their target genes, as global inhibition of the pathway is toxic. Here, we provide an overview on the role of aberrant NF-κB activation in aggressive lymphoid malignancies and discuss the potential importance of individual NF-κB subunits in the pathogenesis of tumor subtypes. View Full-Text
Keywords: nuclear factor-κB; B-cell lymphoma; germinal center; lymphomagenesis; therapeutic nuclear factor-κB; B-cell lymphoma; germinal center; lymphomagenesis; therapeutic

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kennedy, R.; Klein, U. Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies. Cells 2018, 7, 189.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top